| Literature DB >> 34083705 |
Q Mapipa1,2, T O Digban1,2, N E Nnolim1,2, U U Nwodo3,4.
Abstract
Hospital wastewater (HWW) harbours diverse microbial species and a miscellany of genome that would facilitate the emergence of novel pathogen upon genome integration that manifests novel traits in infectious pathogens. The study aimed to determine the antibiogram, and virulence signatures of Pseudomonas aeruginosa (P. aeruginosa) recovered from selected agrestic hospital effluents in Eastern Cape, South Africa. Thirty-six (36) wastewater samples were collected from selected hospital drains between February 2018 and April 2018, processed and analyzed by culture-dependent methods for the isolation of P. aeruginosa. The identity confirmation of isolates was achieved by amplification of oprl and oprL genes. Antibiogram was done using standard disk diffusion technique of Kirby-Bauer as approved by CLSI 2018 guidelines. Virulence signatures (lasA, lasB, toxA, popB) among isolates were analysed using polymerase chain reaction. A total of 54 P. aeruginosa isolates were confirmed by amplification of oprl and oprL genes in the hospital wastewater effluent samples. The isolates showed a 100% susceptibility to gentamicin, amikacin and imipenem antimicrobial agents. Ceftazidime recorded the most resistance (63%) against the isolates studied. Other antibiotics had a resistance range of 7% and 35%. The MAR index among the isolates revealed a range of 0.23 and 0.38. ToxA virulence gene was detected in all isolates while popB, lasB, lasA were detected in 82%, 75% and 54% of the isolates. This study reveals P. aeruginosa isolates with virulence traits and some strains showing multiple antibiotic resistance. The multiple antibiotic resistance index (MARI) of ≥ 0.2 indicates that the some isolates may have emerged from high-risk sources, thus projecting a risk to public health. However, with the high sensitivity pattern observed among the studied isolates, most of the antibiotics used in the susceptibility tests are not at peril. Hence, the use of these antibiotics is encouraged for treatment of infection attributed to P. aeruginosa. It is also pertinent to initiate strict control and rigid antibiotics therapeutic policy with surveillance programmes for multidrug-resistant pathogens to forestall the development and transmission of resistance traits in the pathogens.Entities:
Year: 2021 PMID: 34083705 PMCID: PMC8175747 DOI: 10.1038/s41598-021-91280-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Total number of P. aeruginosa isolates recovered from the three hospital effluents.
| Organism | Presumptive isolates | Confirmed isolates | Hospital A % | Hospital B % | Hospital C % |
|---|---|---|---|---|---|
| 174 | 54 | 11(20) | 43(80) | 0(0) |
Figure 1Gel electrophoresis of PCR products of oprl gene among P. aeruginosa representatives isolates recovered from HWW effluent. Lane 1: DNA Marker (100 bp). Lane 1: negative control. Lane 2–11: positive isolates of oprl gene (249 bp).
Figure 2Gel electrophoresis of PCR products of oprL gene among P. aeruginosa representatives isolates recovered from HWW effluent. Lane 1: DNA Marker (100 bp). Lane 1: negative control. Lane 2–13: positive isolates of oprL gene (504 bp).
Distribution of the Antimicrobial Susceptibility Pattern of P. aeruginosa isolates.
| Antimicrobial class | Antibiotics | Isolates (n = 54) | ||
|---|---|---|---|---|
| S | I | R | ||
| Aminoglycosides | Gentamicin (10 μg) | 54(100) | 0(0) | 0(0) |
| Tobramycin (10 μg) | 50(93 ) | 0(0) | 4(7) | |
| Amikacin 10 μg) | 54(100) | 0(0) | 0(0) | |
| Fluoroquinolones | Ciprofloxacin (5 μg) | 49(91) | 1(2) | 4(7) |
| Norfloxacin (10 μg) | 48(89) | 2(4) | 4(7) | |
| Ofloxacin (5 μg) | 49(91) | 0(0 ) | 5(9) | |
| Carbapenems | Imipenem (30 μg) | 54(100) | 0(0) | 0(0) |
| Doripenem (30 μg) | 50(93) | 0(0) | 4(7) | |
| Meropenem (30 μg) | 52(96) | 0(0) | 2(3) | |
| Cephalosporins | Ceftazidime (30 μg) | 20(37) | 0(0) | 34(63) |
| Cefepime (30 μg) | 35(65) | 0(0) | 19(35) | |
| Penicillins | Piperacillin (100 μg) | 47(87) | 0(0) | 6(11) |
| β- lactamase inhibitor | Piperacillin-tazobactam (100/10 μg) | 44(81) | 2(3) | 8(15) |
R: Resistant, S: Sensitive, I: Intermediate, n: Number of isolates, the parenthesis value denotes percentage (%).
Multidrug resistance profile of the P. aeruginosa isolates.
| Phenotypic resistance | Number of isolates | MAR index |
|---|---|---|
| TOBR , CIPR, NORR | 3 | 0.23 |
| TOBR , CAZR, FEPR | 12 | 0.23 |
| CIPR, NORR, DORR, FEPR | 7 | 0.31 |
| TOBR, DORR, CAZR, PIPR | 11 | 0.31 |
| CIPR, DORR, FEPR, TZPR | 7 | 0.31 |
| NORR, DORR, FEPR, PIPR | 7 | 0.31 |
| TOBR, CIPR, MEMR, CAZR, TZPR | 11 | 0.38 |
| MEMR, CAZR, PIPR | 9 | 0.23 |
| OFXR, CAZR, PIPR | 13 | 0.23 |
| NORR, FEPR, TZPR | 10 | 0.23 |
TOB tobramycin; CIP ciprofloxacin; NOR norfloxacin; CAZ ceftazidime; FEP cefepime; DOR doripenem; PIP piperacillin; TZP piperacillin-tazobactam; MEM meropenem; OFX ofloxacin; IPM: imipenem; AMK amikacin; GEN gentamicin.
Figure 3Gel electrophoresis of PCR products of toxA gene among P. aeruginosa representatives isolates recovered from HWW effluent. Lane 1: DNA Marker (100 bp). Lane 1: negative control. Lane 2–11: positive isolates of toxA gene (396 bp).
Figure 4Gel electrophoresis of PCR products of popB gene among P. aeruginosa representatives isolates recovered from HWW effluent. Lane 1: DNA Marker (100 bp). Lane 2–11: positive isolates of popB gene (1200 bp).
Figure 5Gel electrophoresis of PCR products of lasB gene among P. aeruginosa representatives isolates recovered from HWW effluent. Lane 1: DNA marker (100 bp). Lane 2–11: positive isolates of lasB gene (1220 bp).
Figure 6Gel electrophoresis of PCR products of lasA gene among P. aeruginosa representatives isolates recovered from HWW effluent. Lane 1: DNA marker (100 bp). Lane 1–11: positive isolates of lasA gene (1075 bp).
Figure 7Prevalence of virulence genes among all confirmed P. aeruginosa isolates.
Distribution of virulence genes among the P. aeruginosa isolates.
| Isolate code | ||||
|---|---|---|---|---|
| QKP1 | + | + | + | + |
| QKP2 | + | + | − | − |
| QKP3 | + | + | + | + |
| QKP4 | + | + | + | − |
| QKP5 | + | + | + | + |
| QKP6 | + | − | + | + |
| QKP7 | + | − | + | − |
| QKP8 | + | − | + | − |
| QKP9 | + | + | + | + |
| QKP10 | + | + | − | − |
| QKP11 | + | + | + | + |
| QKP12 | + | − | − | + |
| QKP13 | + | + | − | + |
| QKP14 | + | + | + | + |
| QKP15 | + | − | − | + |
| QKP16 | + | + | + | + |
| QKP17 | + | + | + | + |
| QKP18 | + | + | + | + |
| QKP19 | + | + | + | + |
| QKP20 | + | + | + | + |
| QKP21 | + | + | + | + |
| QKP22 | + | + | + | − |
| QKP23 | + | + | + | − |
| QKP24 | + | + | − | + |
| QKP25 | + | + | + | + |
| QKP26 | + | − | + | − |
| QKP27 | + | + | + | − |
| QKP28 | + | + | + | − |
| QKP29 | + | + | − | − |
| QKP30 | + | + | + | + |
| QKP31 | + | + | + | + |
| QKP32 | + | − | − | − |
| QKP33 | + | + | + | − |
| QKP34 | + | − | + | − |
| QKP35 | + | + | + | + |
| QKP36 | + | + | + | − |
| QKP37 | + | + | − | − |
| QKP38 | + | + | + | − |
| QKP39 | + | + | + | − |
| QKP40 | + | + | − | − |
| QKP41 | + | + | − | − |
| QKP42 | + | + | + | − |
| QKP43 | + | + | + | − |
| QKP44 | + | + | + | − |
| QKP45 | + | + | + | + |
| QKP46 | + | + | + | + |
| QKP47 | + | + | + | + |
| QKP48 | + | + | − | + |
| QKP49 | + | − | + | + |
| QKP50 | + | + | + | + |
| QKP51 | + | − | − | + |
| QKP52 | + | + | + | + |
| QKP53 | + | + | + | + |
| QKP54 | + | + | + | − |
Oligonucleotide primers used for the amplification of oprl and oprL genes.
| Primer | Oligonucleotide primer (5′ → 3′) | Target gene | Fragment size (bp) | Ref |
|---|---|---|---|---|
PS1-F PS2-R | ATGAACAACGTTCTGAAATTC CTTGCGGCTGGCTTTTTCCA | 249 | [ | |
PAL1-F PAL1-R | ATGGAAATGCTGAAATTCGGC CTTCTTCAGCTCGACGCGACG | 504 | [ |
Oligonucleotide primers used in the detection of virulence genes for P. aeruginosa.
| Primer Sequences (5′ → 3′) | Target gene | Fragment size (bp) | Annealing temp °C | Ref |
|---|---|---|---|---|
F-GACAACGCCCTCAGCATCACCAGC R-CGCTGGCCCATTCGCTCCAGCGCT | 396 | 68 | [ | |
F-GCAGCACAAAAGATCCC R-GAAATGCAGGTGCGGTC | 1075 | 57 | [ | |
F- ACAGGTAGAACGCACGGTTG R- GATCGACGTGTCCAAACTCC | 1220 | 50 | [ | |
F- TTTGGATCCATGAATCCGATAACGCTT R- TTTGAATTCTCAGATCGCTGCCGGTCG | 1200 | 55 | [ |